# Kawasaki Disease

Kawasaki disease requires prompt clinical recognition and coronary surveillance because no confirmatory test exists, incomplete presentations remain at risk for coronary aneurysm, and treatment should not be deferred for a negative early echocardiogram or rigid completion of fever-duration criteria.

**Clinical question:** How should clinicians recognize, treat, and monitor Kawasaki disease to limit coronary artery complications?

Updated: 2026-08-21T01:30:45.406701+00:00

## What matters in practice
- Kawasaki disease is a clinical diagnosis; no diagnostic laboratory test is available, and a negative early echocardiogram does not exclude disease. [7][9]
- Do not defer diagnosis or treatment solely to satisfy the historic fever duration when the clinical syndrome is convincing. [7]
- Incomplete presentations with systemic inflammation can still carry coronary artery aneurysm risk and warrant echocardiographic evaluation. [7]
- Coronary aneurysms occur in approximately 20% to 25% of untreated patients; IVIG plus aspirin reduces coronary abnormalities. [4][8]
- Echocardiography is recommended at diagnosis and again 6 to 8 weeks after illness onset; an additional study at 10 to 14 days is recommended in the cited review. [7]

## Diagnose clinically and act before coronary injury evolves

The central error is delayed treatment of a compatible inflammatory syndrome while awaiting diagnostic certainty.

There is no confirmatory test for Kawasaki disease (KD). North American clinical criteria require fever plus four of five principal clinical features; classic descriptions use at least 5 days of fever, but this duration should not force delay when the phenotype is sufficiently convincing. [7][14]

Principal manifestations include polymorphous rash, bilateral nonpurulent conjunctivitis, oral mucosal erythema or strawberry tongue, extremity erythema or edema, and unilateral cervical lymphadenopathy. [8] KD is an acute systemic vasculitis with particular clinical importance because coronary artery aneurysms are its major morbidity-producing complication. [8]

Laboratory findings support systemic inflammation but do not establish KD. Elevated C-reactive protein, erythrocyte sedimentation rate, or leukocytosis should heighten concern in a child with incomplete clinical features. Reported associated findings include early transaminase elevation, sterile pyuria, and thrombocytosis. [7][18]
- Treat the diagnosis as probabilistic: compatible phenotype plus inflammation may justify action before all classic criteria accumulate. [7]
- Obtain echocardiography promptly, but do not use a normal early study to rule out KD or postpone treatment. [7][16]
- Include multisystem inflammatory syndrome in children (MIS-C) in the differential diagnosis; it was specifically added to the updated American Heart Association diagnostic framework. [1]

### Incomplete Kawasaki disease

Incomplete KD should be considered when a child has fever, some principal manifestations, and objective inflammation but does not fulfill complete clinical criteria. These patients can develop coronary artery aneurysms; early echocardiography may demonstrate coronary vasculitis, but its absence does not exclude the diagnosis. [7]

Coronary findings may carry decisive diagnostic weight in incomplete disease, although practice varies internationally. [13] In U.S. practice, involve pediatric cardiology and clinicians experienced in KD when the clinical-inflammatory pattern is concerning, particularly in infants and younger children, who may have greater coronary involvement risk. [12]
- Do not label an incomplete presentation as low risk merely because fewer mucocutaneous findings are present. [7]
- Escalate assessment when fever and inflammation persist, clinical features accrue sequentially, or coronary abnormalities are identified. [7][16]

*Clinical features that should prompt evaluation for Kawasaki disease. [7][8][14]*

| Finding | Interpretation and next action |
| --- | --- |
| Fever with at least four principal clinical features | Meets North American clinical framework for complete KD; obtain echocardiography and initiate timely KD-directed management. [7] |
| Fever with fewer principal features plus elevated CRP, ESR, or leukocytosis | Consider incomplete KD; evaluate for coronary involvement and avoid reassurance from a negative early echocardiogram. [7] |
| Coronary artery abnormality on echocardiography | Supports KD in the appropriate clinical context and identifies a patient requiring risk-stratified cardiovascular follow-up. [7][8] |
| Kawasaki-like phenotype with concern for SARS-CoV-2-associated hyperinflammation | Evaluate MIS-C as an alternative or overlapping diagnosis; coronary aneurysms and KD-like features have been reported in MIS-C. [1][6] |

## Use IVIG-based treatment promptly and identify treatment resistance

Acute therapy aims to suppress inflammation and reduce coronary artery injury.

Intravenous immune globulin (IVIG) and aspirin are established acute therapy. Randomized evidence indicates that IVIG plus aspirin reduces coronary artery abnormalities and systemic inflammation in acute KD. [4] A cited treatment report describes 2 g/kg IVIG as a single infusion as the standard initial regimen, but the supplied excerpts do not provide sufficient evidence to specify aspirin dose, duration, contraindications, or local protocol details. [20]

Failure to respond to initial IVIG identifies a group at increased risk for cardiac complications. [20] Second IVIG, infliximab, and corticosteroids have all been used for IVIG-resistant KD. [21] Selection should be directed with pediatric rheumatology and cardiology because the supplied sources do not establish a universal preferred rescue regimen.
- Do not delay IVIG-based therapy for a normal initial echocardiogram when clinical suspicion is high. [7][16]
- Recognize IVIG nonresponse as a coronary-risk signal requiring reassessment and escalation rather than observation alone. [20][21]
- Primary adjunctive therapy may be considered in selected high-risk patients, but optimal treatment for patients with coronary Z score at least 2.5 at diagnosis remains unsettled. [20]

### Adjunctive anti-inflammatory therapy

Evidence for initial treatment intensification is heterogeneous. In Japanese patients predicted to be IVIG-unresponsive, adding glucocorticoids to IVIG reportedly reduced the probability of coronary artery aneurysm. [20] Generalizability depends on the risk-stratification method and practice setting.

A phase 3 randomized trial of infliximab added to standard therapy reported less treatment resistance than placebo and no infusion-attributable serious adverse events in the supplied excerpt. [22] These data support infliximab as an option in selected settings but do not establish dosing, U.S. labeling status, or universal first-line use from the supplied evidence.
- Corticosteroid benefit cited here is strongest for Japanese children selected as high risk by multivariable prediction scores. [20]
- Infliximab, repeat IVIG, and corticosteroids are all reported options for IVIG-resistant disease; treatment choice remains individualized. [21]

*Acute treatment decisions supported by the supplied evidence. [4][20][21][22]*

| Clinical situation | Evidence-informed action | Important limitation |
| --- | --- | --- |
| Suspected acute KD | Initiate IVIG plus aspirin-based treatment promptly when KD is diagnosed clinically; this combination reduces coronary abnormalities. [4] | The supplied sources do not support a complete aspirin dosing or monitoring protocol. |
| High coronary risk or coronary Z score at least 2.5 at presentation | Consider first-line intensification in expert consultation. [20] | Optimal proactive regimen is not established. [20] |
| IVIG-resistant KD | Reassess coronary status and consider repeat IVIG, infliximab, or corticosteroids with subspecialty involvement. [20][21] | The excerpts do not define a preferred sequence or regimen. |

## Use serial echocardiography to define coronary risk

Coronary status—not resolution of mucocutaneous findings—determines long-term cardiovascular surveillance.

All patients with KD should undergo echocardiography at diagnosis and at 6 to 8 weeks after illness onset; the cited review also recommends an intermediate echocardiogram at 10 to 14 days. [7] Early imaging can identify coronary vasculitis in incomplete presentations, but a normal early examination does not exclude KD. [7]

Coronary artery dimensions should be interpreted using body-size-adjusted Z scores. The supplied source categorizes dilation as Z score at least 2.0 to less than 2.5, small aneurysm as at least 2.5 to less than 5.0, medium aneurysm as at least 5 to less than 10 with absolute luminal dimension under 8 mm, and uses persistent Z scores below 2 as a no-involvement category. [8]

Young children may be at greatest risk of coronary involvement. [12] Patients with aneurysms require continued cardiology-directed surveillance because coronary artery aneurysms account for substantial KD morbidity and mortality, and myocardial infarction risk is highest soon after disease onset. [1][8]
- Document coronary anatomy at baseline even when treatment begins before imaging is completed. [7][16]
- Repeat imaging after treatment because early coronary findings can be absent or evolve during the acute illness. [7]
- Use the coronary Z-score category to communicate risk and determine the intensity of cardiology follow-up. [8]

*Coronary artery categories cited in a clinical management algorithm. [8]*

| Category | Z-score definition | Clinical implication |
| --- | --- | --- |
| No involvement at any time | Z score always less than 2. [8] | Follow-up pathway differs from aneurysm categories. [8] |
| Dilation only | Z score at least 2.0 to less than 2.5. [8] | Requires distinction from aneurysmal disease in longitudinal assessment. [8] |
| Small aneurysm | Z score at least 2.5 to less than 5.0. [8] | Represents coronary artery involvement requiring risk-stratified follow-up. [8] |
| Medium aneurysm | Z score at least 5 to less than 10 with absolute luminal dimension less than 8 mm. [8] | Requires more intensive cardiovascular assessment than dilation alone. [8] |

## Separate KD from MIS-C without missing either disorder

Overlapping inflammatory and mucocutaneous phenotypes require parallel diagnostic thinking.

MIS-C is an important differential diagnosis in children with KD-like illness and has been incorporated into updated KD guidance. [1] In a U.S. MIS-C cohort, 40% had KD-like features and 8% had coronary artery aneurysms defined by Z score of at least 2.5. [6]

The distinction matters because treatment evidence and disease trajectory differ. In a comparative treatment study, initial treatment with IVIG alone in MIS-C was associated with delayed recovery and increased coronary aneurysm risk relative to treatment approaches that included glucocorticoids; this evidence applies to MIS-C rather than establishing treatment for classic KD. [3]
- When considering KD, actively assess for MIS-C rather than assuming mucocutaneous findings establish classic KD. [1][6]
- Avoid extrapolating MIS-C treatment data directly to classic KD or vice versa. [3][4]

*KD and MIS-C overlap relevant to diagnostic assessment. [1][3][6]*

| Issue | Decision relevance |
| --- | --- |
| KD-like clinical features in MIS-C | Reported in 40% of a U.S. MIS-C cohort; phenotype overlap cannot independently distinguish the disorders. [6] |
| Coronary aneurysms in MIS-C | Reported in 8% of the cited U.S. cohort using Z score at least 2.5; coronary imaging remains relevant in suspected MIS-C. [6] |
| Initial immunomodulation | Comparative MIS-C evidence suggests IVIG alone may be inferior to IVIG plus glucocorticoids for recovery and coronary outcomes; do not treat this as KD-specific evidence. [3] |

## Common questions

### Can a normal echocardiogram exclude Kawasaki disease?

No. Early echocardiography may show coronary vasculitis in incomplete KD, but a negative study does not exclude the diagnosis and should not delay treatment when clinical suspicion is high. [7][16]

### When should incomplete Kawasaki disease be suspected?

Consider it in a febrile child with fewer than the full set of principal clinical features plus systemic inflammation, especially elevated CRP, ESR, or leukocytosis. Coronary disease can occur despite incomplete clinical criteria. [7]

### What is the standard initial IVIG regimen in Kawasaki disease?

A cited treatment source describes 2 g/kg IVIG as a single infusion as standard initial therapy. IVIG plus aspirin reduces coronary artery abnormalities, but the supplied excerpts do not support a complete aspirin dosing regimen. [4][20]

### How often should echocardiography be performed after Kawasaki disease diagnosis?

The cited review recommends echocardiography at diagnosis, at 10 to 14 days after disease onset, and at 6 to 8 weeks after onset. [7]

### Which patients warrant concern for IVIG resistance?

Patients who fail to respond to initial IVIG are at increased risk for cardiac complications. Repeat IVIG, infliximab, and corticosteroids have been advocated, but the supplied sources do not establish a universal preferred rescue sequence. [20][21]

## References
1. Diagnosing and Managing Kawasaki Disease | NEJM Clinician — clinician.nejm.org — https://clinician.nejm.org/diagnosing-managing-kawasaki-disease-nejm-jw.NA58286
2. Cardiovascular Risk Reduction in High-Risk Children | NEJM Clinician — clinician.nejm.org — https://clinician.nejm.org/PA200704040000001
3. Treatment of Multisystem Inflammatory Syndrome in Children — www.nejm.org — https://www.nejm.org/doi/full/10.1056/NEJMoa2102968
4. Randomized Trial of Pulsed Corticosteroid Therapy for ... — www.nejm.org — https://www.nejm.org/doi/full/10.1056/NEJMoa061235
5. Multisystem Inflammatory Syndrome in Children — Initial ... — www.nejm.org — https://www.nejm.org/doi/full/10.1056/NEJMoa2102605
6. Multisystem Inflammatory Syndrome in U.S. Children and ... — www.nejm.org — https://www.nejm.org/doi/full/10.1056/NEJMoa2021680
7. Management of Kawasaki disease | Archives of Disease in Childhood — adc.bmj.com — https://adc.bmj.com/content/99/1/74
8. Kawasaki disease - Symptoms, diagnosis and treatment — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-us/236
9. Kawasaki disease: how to distinguish from other febrile ... — ep.bmj.com — https://ep.bmj.com/content/105/3/152
10. A machine-learning algorithm for diagnosis of multisystem ... — www.thelancet.com — https://www.thelancet.com/journals/landig/article/PIIS2589-7500(22)00149-2/fulltext
11. the KD-CAA prevention (KD-CAAP) trial — www.thelancet.com — https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(26)00297-X/fulltext
12. Subgroups of children with Kawasaki disease: a data ... — www.thelancet.com — https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(23)00166-9/fulltext
13. Diagnostic approaches to Kawasaki disease worldwide — academic.oup.com — https://academic.oup.com/rheumatology/article/65/7/keag340/8719060
14. Incomplete (atypical) Kawasaki disease — journals.lww.com — https://journals.lww.com/pidj/fulltext/2002/06000/incomplete__atypical__kawasaki_disease.15.aspx
15. Clinical prediction model: Multisystem inflammatory syndrome ... — shmpublications.onlinelibrary.wiley.com — https://shmpublications.onlinelibrary.wiley.com/doi/10.1002/jhm.13290
16. Diagnosis of Kawasaki disease - Singh - 2018 — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/1756-185X.13224
17. Multimodal Echocardiographic Assessment in Intravenous ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/echo.70589
18. Revision of diagnostic guidelines for Kawasaki disease ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/ped.14326
19. Aspirin Dose in Kawasaki Disease: The Ongoing Battle — acrjournals.onlinelibrary.wiley.com — https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/acr.23504
20. Effective infliximab therapy for the early regression of ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0167527317380567
21. Infliximab versus second intravenous immunoglobulin for ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2352464221002704
22. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0140673613622989
23. Articles Pharmacologic interventions for Kawasaki disease ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S235239642200130X
24. Value of cystatin C for Kawasaki disease with coronary ... — journals.lww.com — https://journals.lww.com/tp/_layouts/15/oaks.journals/downloadpdf.aspx?an=01727407-202504000-00003

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.